Results 21 to 30 of about 110,931 (189)

Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma [PDF]

, 2011
Purpose: To assess the duration of the effect of intracameral bevacizumab in patients presenting with rubeosis iridis and neovascular glaucoma (NVG). Methods: Retrospective analysis of 24 consecutive eyes of 24 patients with decompensated NVG (> 21 mm Hg)
Haritoglou, Christos, Wolf, Armin, Ulbig, Michael, Christos Haritoglou, Jagow, Burkhard von, Burkhard von Jagow, Michael Ulbig, Armin Wolf   +7 more
core   +1 more source

Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema [PDF]

, 2010
Background: Our purpose was to compare the effect of triamcinolone and bevacizumab (Avastin) on the retinal thickness and functional outcome in patients with diabetic macular edema. Methods and Materials: A collective of 32 patients, who had been treated
Haritoglou, Christos, Ulbig, Michael W., Kook, Daniel, Wolf, Armin, Neubauer, Aljoscha Steffen, Kreutzer, Thomas C., Al Saeidi, Rashid   +6 more
core   +1 more source

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update [PDF]

, 2008
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of ...
Middleton, M. (Mark), Corrie, P, Middleton, M, Dunn, J., East, C, Lorigan, P; id_orcid, Hern, A., Biswas, S., Wrigley, J., Lorigan, P., Wrigley, J, Dunn, Janet A., Marshall, A. (Andrea), Corrie, P., East, C., Marshall, A.   +15 more
core   +1 more source

Bevacizumab (Avastin) [PDF]

American Journal of Neuroradiology, 2009
Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
openaire   +2 more sources

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]

, 2013
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Erik Engel, Engel, Erik, Jürgen Dunst, Florian Würschmidt, Kathrin Dellas, Arnold, Dirk, Dirk Arnold, Michael Richter, Richter, Michael, Rödel, Claus, Thomas Reese, Höhler, Thomas, Thomas Höhler, Claus Rödel, Dellas, Kathrin, Reese, Thomas, Wagner, Wolfgang, Dunst, Jürgen, Würschmidt, Florian, Wolfgang Wagner   +19 more
core   +1 more source

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series

Case Reports in Neurology, 2016
Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields ...
George Ansstas, David D. Tran
doaj   +1 more source

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab

Drugs in R&D, 2023
Background BAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several different cancers, including metastatic colorectal cancer. A comprehensive physicochemical and functional
Di Cao, Chunping Deng, Guangying Wang, Xiong Mei, Jianhua Xie, Yuanmei Liu, Yujie Liu, Yili Yang, Shengfeng Li, Cuihua Liu   +9 more
doaj   +1 more source

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study [PDF]

, 2014
Background: Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of ...
N. Davidson (7671467), J. P. Nobes (7671491), P. Lorigan (7671500), Harries, M., C. G. Kelly (7671473), A. Marshall (7671452), M. R. Middleton (7671458), Dunn, Janet A, Houston, Stephen J, Board, Ruth E., Steve Nicholson (7671470), Lorigan, P., Waterston, A.M., Nobes, Jenny P., Gore, M.E., Kelly, Charles G, Danson, S., Nathan, Paul D, Nathan, Paul D., Kumar, S., Middleton, Mark R., Davidson, Neville, Marples, M., Nobes, Jenny P, Waterston, Ashita M, Young, G., Dunn, J., Nathan, P.D., Lorigan, Paul; id_orcid, Houston, S., Danson, Sarah J, M. Gore (7671464), Davidson, D., Board, R.E., M. Marples (7671476), Dunn, Janet A., Nobes, J.P., Marshall, E., Corrie, P., S. J. Danson (7671479), Marshall, A., Middleton, Mark R, Board, Ruth E, Middleton, M.R., Marshall, Ernest, Gore, Martin, Marples, Maria, Corrie, Pippa G, P. D. Nathan (7671461), G Young (7671497), E. Marshall (7241588), Houston, Stephen J., Young, Gemma, Nicholson, Steve, A. M. Waterston (7671488), Kelly, Charles G., P. G. Corrie (7671449), S. J. Houston (7671482), Kelly, C.G., Corrie, Pippa G., M. Harries (7671494), Marshall, Andrea, Kumar, Satish, S. Kumar (746162), Nicholson, S., Waterston, Ashita M., R. E. Board (7671485), Harries, Mark, Danson, Sarah J., Marshall, A. (Andrea)‏, Lorigan, Paul, J. A. Dunn (7671455)   +71 more
core   +1 more source

Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization

Veterinary Sciences, 2023
Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to ...
Ulrike Lessiak, Barbara Pratscher, Alexander Tichy, Barbara Nell   +3 more
doaj   +1 more source